139 related articles for article (PubMed ID: 17449237)
1. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B.
Kalla C; Scheuermann MO; Kube I; Schlotter M; Mertens D; Döhner H; Stilgenbauer S; Lichter P
Eur J Cancer; 2007 May; 43(8):1328-35. PubMed ID: 17449237
[TBL] [Abstract][Full Text] [Related]
2. Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes.
Kalla C; Nentwich H; Schlotter M; Mertens D; Wildenberger K; Döhner H; Stilgenbauer S; Lichter P
Genes Chromosomes Cancer; 2005 Feb; 42(2):128-43. PubMed ID: 15543602
[TBL] [Abstract][Full Text] [Related]
3. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
[TBL] [Abstract][Full Text] [Related]
4. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
[TBL] [Abstract][Full Text] [Related]
5. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
[TBL] [Abstract][Full Text] [Related]
7. Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders.
Eclache V; Caulet-Maugendre S; Poirel HA; Djemai M; Robert J; Lejeune F; Raphaël M
Cancer Genet Cytogenet; 2004 Jul; 152(1):72-6. PubMed ID: 15193446
[TBL] [Abstract][Full Text] [Related]
8. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia.
Dickinson JD; Smith LM; Sanger WG; Zhou G; Townley P; Lynch JC; Pavletic ZS; Bierman PJ; Joshi SS
Br J Haematol; 2005 Feb; 128(4):460-71. PubMed ID: 15686453
[TBL] [Abstract][Full Text] [Related]
9. PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas.
Zhu Y; Loukola A; Monni O; Kuokkanen K; Franssila K; Elonen E; Vilpo J; Joensuu H; Kere J; Aaltonen L; Knuutila S
Leuk Lymphoma; 2001 Mar; 41(1-2):177-83. PubMed ID: 11342371
[TBL] [Abstract][Full Text] [Related]
10. Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia.
Auer RL; Starczynski J; McElwaine S; Bertoni F; Newland AC; Fegan CD; Cotter FE
Genes Chromosomes Cancer; 2005 May; 43(1):1-10. PubMed ID: 15672409
[TBL] [Abstract][Full Text] [Related]
11. ATM mutations in B-cell chronic lymphocytic leukemia.
Bullrich F; Rasio D; Kitada S; Starostik P; Kipps T; Keating M; Albitar M; Reed JC; Croce CM
Cancer Res; 1999 Jan; 59(1):24-7. PubMed ID: 9892178
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.
Starostik P; Manshouri T; O'Brien S; Freireich E; Kantarjian H; Haidar M; Lerner S; Keating M; Albitar M
Cancer Res; 1998 Oct; 58(20):4552-7. PubMed ID: 9788599
[TBL] [Abstract][Full Text] [Related]
13. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
[TBL] [Abstract][Full Text] [Related]
14. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
15. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
[TBL] [Abstract][Full Text] [Related]
16. Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia.
Shackelford RE; Bhalodia AR; Cotelingam JD; Veillon DM; Lowery-Nordberg M
Med Hypotheses; 2006; 66(3):509-12. PubMed ID: 16326028
[TBL] [Abstract][Full Text] [Related]
17. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
[TBL] [Abstract][Full Text] [Related]
18. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
19. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.
Tamaki M; Goi T; Hirono Y; Katayama K; Yamaguchi A
Oncol Rep; 2004 Mar; 11(3):655-9. PubMed ID: 14767517
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
